Transforming growth factor (TGF) ␤1 has been suggested to have an important role in cavernous fibrosis and resultant erectile dysfunction. For further elucidation of TGF␤1 signaling in association with cavernous fibrosis, we developed a rat model of cavernous fibrosis using TGF␤1-producing NIH 3T3 fibroblasts (NIH 3T3-TGF␤1). The NIH 3T3-TGF␤1 cells were injected into male Sprague-Dawley rats intracavernously. Masson trichrome staining at 20 days postinjection showed multiple fibrous scars in the rats injected with the NIH 3T3-TGF␤1 cells (group 3), whereas no histological evidence of cavernous fibrosis was found in the control rats (group 1) or the recombinant human TGF␤1 protein-injected rats (group 2). Immunohistochemical staining revealed a higher expression of TGF␤1 and its type II receptor in group 3 than in groups 1 and 2. Electrostimulation of the cavernous nerve revealed that the maximal intracavernous pressure was significantly lower in group 3 than in groups 1 and 2 (P Ͻ 0.01). The expression of transgenic TGF␤1 mRNA continued to 10 days after injection of the cells. The NIH 3T3-TGF␤1 cells sufficiently induced relatively long-lasting cavernous fibrosis. This novel animal model may contribute to future investigations of the pathogenesis of penile fibrosis associated with TGF␤1 signaling and the development of new therapeutics targeting this pathway. male sexual function, penis
INTRODUCTION
The trabeculae of the corpora cavernosa consist primarily of smooth muscle and extracellular connective tissue matrix [1, 2] . The percentage of trabecular smooth muscle in normal men reportedly ranges from 42% to 50%. In patients with vasculogenic erectile dysfunction (ED), a decrease in the percentage of trabecular smooth muscle content has been observed, with values ranging from 10% to 36% [2] . This reduction can lead to ED, in that if the cavernous smooth muscle content is less than a critical amount, the veno-occlusive mechanism inevitably fails to operate, regardless of the extent of smooth muscle relaxation [1] .
An understanding of the factors that alter the functional smooth muscle-connective tissue balance is of paramount importance in the continuing development of therapeutic agents for the treatment of vasculogenic ED. Recently, much attention has been focused on the role of transforming growth factor (TGF) ␤1 as a fibrogenic cytokine to induce fibrosis in a variety of organs. This protein has been shown to increase collagen synthesis in human corpus cavernosal smooth muscle cell by 2.5-to 4.5-fold [3] . Additionally, TGF␤1 is overexpressed in the tunica albuginea of men suffering from veno-occlusive dysfunction [1] and in plaques obtained from those with Peyronie disease [4] .
To establish an animal model of cavernous fibrosis, Nehra et al. [5] have shown that the intracavernosal injection of recombinant human (rh) TGF␤1-impregnated alginate microspheres into the rabbit corpus cavernosum resulted in a dose-dependent decrease in the percentage of corporal smooth muscle, but this change lasted only for a short period. This can be explained, in part, by the short-term effects of the rhTGF␤1 protein, which result from the vascular nature of the corpus cavernosum and the short halflife of the free TGF␤1 in the bloodstream. Therefore, a new method for long-term, cost-effective delivery of such cytokines is essential for the establishment of a long-term cavernous fibrosis model that is useful in investigating and understanding TGF␤1 signaling. Recently, Lee et al. [6] reported that fibroblasts containing an exogenous TGF␤1 gene (NIH 3T3-TGF␤1 cells) successfully induced cartilage regeneration when injected into the knee joint of rabbits with artificial cartilage defects and were able to express the transgene for at least 4 wk after injection in vivo.
Therefore, we hypothesized that the injection of NIH 3T3 fibroblasts containing a transgene, TGF␤1, into the corpus cavernosum could achieve a long-term, sustained production of TGF␤1, which could cause cavernous fibrosis with resultant ED.
MATERIALS AND METHODS

Development of NIH 3T3-TGF␤1 Cells
The NIH 3T3-TGF␤1 cell line was donated by the National Cancer Institute in National Institutes of Health (Bethesda, MD). The technique to establish this cell line has been described previously [6] . Briefly, p-MTMLV␤1 was constructed by cloning a 1.2-kilobase porcine TGF␤1 cDNA into the polylinker site of the replication-defective retroviral vector pMTMLV. The pMTMLV vector was derived from the retroviral vector MFG by deleting entire gag and env sequences as well as some of the package sequence. All the U3 of 5Ј long terminal repeat (LTR) except for 36 base pairs at the 5Ј end was repeated with the metallothionein (MT) promoter [7] . The pMTMLV␤1 and pVSVG were cotransfected into GP293 cells by the calcium phosphate method. After 48 h of culture, the supernatant was filtered (pore size, 0.45 m), and half of it was saved at Ϫ70ЊC for later use. The NIH 3T3 cells were seeded in 60-mm culture dishes, and 18 h later, they were infected with the filtrate plus 8 g/ml of Polybrene (Sigma Chemical Co., St. Louis, MO). After 4 h of incubation, the medium was replaced with fresh medium. Infection was repeated 24 h later with the saved viral supernatant. Transduced cells were cultured in Dulbecco modified Eagle medium with 10% fetal bovine serum, and selection with neomycin (10 M/ml) started 48 h after transfection. The secretion rate of TGF␤1 protein of NIH 3T3-TGF␤1 or NIH 3T3-neo cells was measured by ELISA.
Intracavernosal Injection of NIH 3T3-TGF␤1 Cells
Adult male Sprague-Dawley rats (weight, 200-250 g) were used. Before the experiments, the rats were maintained in standard cages under clean conditions in separate quarters under a 12L:12D photoperiod with free access to water and pellets. The present experiments were approved by the Institutional Animal Care and Use Subcommittee of our university. Rats were randomly assigned to the control group or to treatment groups (Table 1 ). Treatment animals received 1 ϫ 10 5 , 1 ϫ 10 6 , or 3 ϫ 10 6 cells in 0.1 ml of NIH 3T3-TGF␤1 cells, whereas control animals received 3 ϫ 10 6 cells in 0.1 ml of NIH 3T3-neo cells. Based on these initial results, three separate groups of rats were subjected to the next animal experiment: In group 1, culture medium (0.1 ml) was injected into the corpora cavernosa of the rats as a control (n ϭ 12). In group 2, rhTGF␤1 (200 ng in 0.1 ml) was injected into the cavernosa (n ϭ 12). In group 3, NIH 3T3-TGF␤1 cells (3 ϫ 10 6 cells in 0.1 ml) were injected into the cavernosa (n ϭ 36). Using sterile technique, penile skin was incised, and tunica albuginea was exposed. Culture medium, rhTGF␤1 protein, or cells were injected into the cavernosum under magnification (10ϫ to 16ϫ) via a 26-gauge needle. Injection was made into the midportion of the left side of corpus cavernosum of each rat. The incision was closed with 6-0 vicryl sutures. The rats in groups 1 and 2 were killed at 20 days and those in the group 3 at 20, 40, and 60 days after electrical stimulation of cavernous nerve.
Measurement of Erectile Function
The rats from each group were anesthetized with chloral hydrate (20 mg/kg) administered i.p. and were placed on a thermoregulated surgical table. Supplemental doses of chloral hydrate were administered as needed to maintain a uniform level of anesthesia. A carotid artery was cannulated (PE-50 tubing) for the measurement of systemic arterial pressure. The animal was placed in a supine position, and the bladder and prostate were exposed through a midline abdominal incision. With the aid of a Zeiss dissecting microscope, the major pelvic ganglion and cavernous nerve were identified posterolaterally to the prostate on one side, and bipolar platinum-wire electrodes were placed around the cavernosal nerve for electrical stimulation. The penis was denuded of skin, and a 26-gauge needle filled with 250 U/ml of heparin was inserted into one side of the corpus cavernosum for monitoring of the intracavernous pressure (ICP). Systemic arterial and intracavernosal blood pressures were measured with a Statham P23 pressure transducer connected to a computerized system for data acquisition (Biopac Systems, Goleta, CA), which was interfaced to a personal computer for recording and data analysis. Each rat underwent electrical field stimulation at a frequency of 12 Hz, a pulse width of 1 msec, and a duration of 1 min. The application of 5 V was used in the current protocol to achieve a significant and consistent erectile response. During tumescence, maximal ICP and latency to maximal erection were recorded.
Tissue Harvest
After the functional study was completed, a midportion of penile segment was harvested for histologic staining. The cavernous tissue specimens were immediately fixed in 10% formalin phosphate buffer solution before paraffin embedding. The specimens were stained with Masson trichrome or hematoxylin-eosin.
Immunohistochemical Staining for Mouse Major Histocompatibility Class I, ␣-Smooth Muscle Actin, TGF␤1, and Its Type II Receptor Sections, prepared as described above, were deparaffinized and hydrated by sequential incubations in xylene and ethanol. After washing in 918 RYU ET AL. 1ϫ PBS for 2 min, the sections were blocked with 3% H 2 O 2 for 10 min. The primary antibody against mouse major histocompatibility class I (Accurate Chemical, Westbury, NY), ␣-smooth muscle actin (␣-SMA; DAKO, Trappes, France), TGF␤1 (Sigma), or TGF␤1 receptor type II (TGF␤RII; Santa Cruz Biotechnology Inc., Santa Cruz, CA) was applied to the sections and incubated for 1 h. Control sections were incubated without the primary antibody at this step. The sections were washed and blocked with 5% milk in 1ϫ PBS for 20 min before incubation with the horseradish peroxidase-conjugated secondary antibody. The chromogen reaction was performed with 0.05% diaminobenzidine in 1ϫ PBS for 5 min. The sections were subsequently stained with hematoxylin and then mounted.
Smooth Muscle Quantification Using Automated Computer Morphometric Analysis System
For better identification of smooth muscle cells lining the cavernosal spaces, we used sections immunolabeled with the anti-␣-SMA antibody, which is specific for a single ␣-actin isoform. Quantitative analysis of smooth muscle and collagen fibers in cavernous tissue was done with an image analyzer system combined with a light microscope equipped with a video camera at a final magnification of 40ϫ. The images were discriminated interactively, and the measurements were performed on the resulting binary images. We divided the total area of the corpus cavernosum into four fields, and then the relative area of smooth muscle cells was determined in each field as described previously [2] . We analyzed five slides containing two penile sections each per animal.
Reverse Transcriptase-Polymerase Chain Reaction Analysis
The corpus cavernosal tissues were carefully dissected free from the surrounding tunica albuginea at 3, 5, 7, 10, 15, 20, and 30 days after injection of NIH 3T3-TGF␤1 or control NIH 3T3-neo cells, and mRNA was extracted from the cavernosal tissue each time. First-strand cDNA was synthesized using reverse transcriptase (RT) with oligo(dT) primers, and then the polymerase chain reaction (PCR) was performed with an LTR-specific primer (forward, 5Ј-TCG TCC GGG ATC GGG AGA-3Ј) and TGF␤1-specific primer (reverse, 5Ј-TCG CGG GRA CTG TTG TAA AGA GC-3Ј) for 35 cycles. Each cycle consists of a denaturation step at 94ЊC for 1 min, an annealing step at 56ЊC for 2 min, and an extension step at 72ЊC for 3 min. ␤-Actin was used as an internal control. The set of primers for ␤-actin included the following: forward primer, 5Ј-TCT ACA ATG AGC TGC GTG TG-3Ј; reverse primer, 5Ј-AAT GTC ACG CAC GAT TTC CC-3Ј.
Statistical Analysis
Results are expressed as the mean Ϯ SD. The means of more than three groups were compared by ANOVA. The statistical significance of differences between two groups was assessed by the Scheffe test. Probability values of less than 5% were considered to be significant. All statistical analyses were performed using the SPSS-Win 10.0 package (SPSS Inc., Chicago, IL). 
RESULTS
Expression of TGF␤1 in NIH 3T3 Fibroblasts
To explore the possibility of establishing a new cavernous fibrosis model using fibroblasts expressing TGF␤1, NIH 3T3 murine fibroblast cells were infected with recombinant TGF␤1 retroviruses in which the expression of active TGF␤1 was driven by the MT promoter. Several stable cell lines (NIH 3T3-TGF␤1) were generated by G418 selection. The average rates of secretion of TGF␤1 as measured by ELISA from a stable cell line, which was used in the present experiment, was approximately 30 ng per 10 5 cells per 24 h (Fig. 1) .
Expression of Exogenous TGF␤1 In Vivo after Injection
To investigate the expression of exogenous TGF␤1 transcript after injection of the TGF␤1-producing fibroblasts, RT-PCR was performed with mRNA extracted from the cavernosal tissues up to 30 days postinjection. To detect exogenous TGF␤1 only, a set of primers was derived from the retroviral LTR sequence and the 5Ј-end of the TGF␤1 gene of pMTMLV␤1. We found that the expression of exogenous TGF␤1 transcripts peaked at 5 days postinjection and continued to 10 days after injection (Fig. 2) .
Cavernous Histologic Change after Injection of NIH 3T3-TGF␤1 Cells
To determine whether TGF␤1-producing fibroblasts can induce cavernous fibrosis, three different cell numbers of NIH 3T3-TGF␤1 cells (1 ϫ 10 5 , 1 ϫ 10 6 , or 3 ϫ 10 6 in 0.1 ml of PBS) were injected into the cavernosa. Then, the degree of cavernous fibrosis was evaluated by Masson trichrome staining of specimens at 5, 10, 15 and 20 days after injection. Specimen injected with NIH 3T3-neo cells (3 ϫ 10 6 in 0.1 ml) was used as the control. The results showed that the NIH 3T3-TGF␤1 cells sufficiently induced cavernous fibrosis in a dose-dependent manner, whereas the NIH 3T3-neo cells did not show any significant changes in a histological examination (Fig. 3) . At 5 days postinjection, multiple inflammatory nodules were found in the sinusoidal space, which consisted mainly of injected mouse fibroblasts as well as some neutrophils and myofibroblasts. At 10 or 15 days after injection, these inflammatory nodules started to produce collagen fibrils and then formed fibrous scars, which consisted mainly of lymphocytes, plasma cells, and fibroblasts as well as some myofibroblasts (Fig. 4) . In the group injected with the high-dose NIH 3T3-TGF␤1 cells (3 ϫ 10 6 in 0.1 ml), these fibrous scars lasted up to 20 days postinjection and reduced gradually thereafter until 40 days (data not shown).
Based on these preliminary results, we compared the effects of three different groups (rhTGF␤1 protein, NIH 3T3-TGF␤1 cells, and culture medium as the control) on cavernous fibrosis at 20 days postinjection. Examination of serial sections stained with Masson trichrome in the group receiving the NIH 3T3-TGF␤1 cells revealed multiple fibrous scars on the corpus cavernosum, which not only were distributed evenly around the injection site but also were identified bilaterally. However, no histological changes were found in either the rhTGF␤1 protein or the control group (Fig. 5) . Immunohistochemical staining of the cavernosal tissues performed with the TGF␤1 and TGF␤RII antibody 20 days after postinjection of NIH 3T3-TGF␤1 cells showed higher levels of TGF␤1 and TGF␤RII protein expression, especially in the area of fibrosis, compared to the rhTGF␤1 protein or the medium control group (Fig. 6) .
Computer-assisted histomorphometric analysis was used to determine the mean trabecular smooth muscle content for each treatment and the control group. Interestingly, the content of trabecular smooth muscle was increased signif- icantly in the NIH 3T3-TGF␤1 group (15.2% Ϯ 3.7%), especially around the fibrous scars, compared to the culture medium (8.9% Ϯ 3.2%) and the rhTGF␤1 protein group (8.8% Ϯ 1.2%; P Ͻ0.001) (Fig. 7) .
Penile Erection after Injection of NIH 3T3-TGF␤1 Cells
Electrical stimulation of the cavernous nerve in the group injected with the NIH 3T3-TGF␤1 cells elicited a significantly lower maximal ICP and a more prolonged latency to maximal ICP at 20 days postinjection compared to those in the control group. However, a significant recovery of erectile function was noted at 40 and 60 days after injection of the NIH 3T3-TGF␤1 cells. The group injected with the rhTGF␤1 protein did not show any significant difference in erectile function compared to the control group (Table 2) .
DISCUSSION
We undertook the task of developing a rat model of cavernous fibrosis using a cell-mediated approach to gene delivery. This rat model offers several advantages compared to bigger animal models, including the rabbit. The cavernous nerve of the rat can be easily identified and stimulated to assess the erectile response. In addition, rats are less likely to develop wound infection and anesthesia-related complications. Furthermore, this cell-mediated method of gene delivery has advantages over application of the TGF␤1 protein, which has a short half-life with resultant short-term effects and also is very expensive.
The RT-PCR analysis of the cavernosal tissues showed that the fibroblasts containing an exogenous TGF␤1 gene were able to express the transgene for at least 10 days after injection in vivo. This finding suggests that active TGF␤1 proteins secreted from the injected cells can be available for more than 10 days to induce cavernous fibrosis. This sustained expression of the active TGF␤1 protein is believed to be a principal cause of the cavernous fibrosis shown in the present study. To explore whether the fibroblast itself may influence cavernous fibrosis, we also performed a cavernosal injection with NIH 3T3-neo cells that did not contain an exogenous TGF␤1. The results showed that the NIH 3T3-neo cells alone did not induce cavernous fibrosis, suggesting that fibroblasts itself may not be a determining factor for cavernous fibrosis. In the present study, a single dose of rhTGF␤1 protein did not induce cavernous fibrosis or subsequent deterioration of erectile function, which is similar to the results of another rat study (T.F. Lue, personal communication). However, other studies have demonstrated that injection of TGF␤1 protein into the tunica albuginea of the rat induced long-term histological changes to the tunica albuginea similar to those found in human Peyronie disease [8, 9] . Lack of an effect in the present study can be explained by rapid turnover or clearance of TGF␤1 protein because of the vascular nature of the corpus cavernosum. In a rabbit model to establish corporal fibrosis, an intracavernous injection of TGF␤1-impregnated sodium alginate microspheres elicited corporal fibrosis and a significant decrease in the trabecular smooth muscle content for 3-5 days postinjection [5] .
In the present study, the inflammatory response was noted up to 5-10 days after injection of the NIH 3T3-TGF␤1 cells, and fibrotic processes, as evidenced by Masson trichrome stain, began to appear at 10 days postinjection. These fibrous scars lasted up to 20 days postinjection and decreased gradually thereafter. Furthermore, immunohistochemical staining for TGF␤1 and TGF␤RII at 20 days after the injection of NIH 3T3-TGF␤1 cells showed increased immunoreactivity, especially in the fibrous scar, compared to the group injected with the culture medium or the rh-TGF␤1 protein. These results imply that all aspects of the fibrotic disease process have been shown to be regulated by TGF␤1, including the initial inflammatory phase in which the infiltrating inflammatory cells and macrophages set the stage for the subsequent fibrotic phase in which the mononuclear cells and activated fibroblasts contribute to the pathogenic accumulation of the matrix [10] . The TGF␤1 induces penile fibrosis via activation of TGF␤RII.
We also performed computer-assisted histomorphometric analysis to determine the mean cavernosal smooth muscle content. Surprisingly, the content of the trabecular smooth muscle was significantly increased, especially around the fibrous scars, in the group injected with the NIH 3T3-TGF␤1 cells compared to the other groups. This is quite an unexpected finding, because TGF␤1 inhibits smooth muscle proliferation. However, it is unclear whether the increase of the smooth muscle content resulted from the compensatory mechanism during the long-lasting fibrotic process, from the influence of other cytokines involved, or from a problem in the cell-mediated approach to gene delivery. This is a major drawback of the present model, because naturally occurring cavernous fibrosis shows a decrease in the smooth muscle content. Additional studies dealing with the effect of a pure TGF␤1 gene on the rat corpus cavernosum or the effect of the NIH 3T3-TGF␤1 cells on other animals, such as the rabbit, may offer explanations for this.
Regarding the erectile function study in the rat at 20 days after injection of NIH 3T3-TGF␤1 cells, the nerve-induced erection was much more compromised compared to the control group. However it gradually recovered to the normal level at 40 and 60 days after injection. This result was well correlated with histological findings, including cavernous fibrosis.
The TGF␤1 has been known to cause fibrotic disease and a resultant functional impairment in a variety of organs, including liver cirrhosis, chronic hepatitis, glomeruolonephritis, and pulmonary fibrosis [11] . Additionally, TGF␤1 signaling is responsible for cavernous fibrosis and vasculogenic ED in an animal model of atherosclerosis [12, 13] .
The multifaceted effects of TGF␤ in promoting fibrosis have led to the suggestion that therapies aimed at reducing the expression or activity of TGF␤ might be efficacious in the treatment or prevention of fibrotic diseases. Several groups have shown a direct correlation between the inhibition of TGF␤ and the abrogation of fibrosis in the skin and lung. In three notable examples, bleomycin-induced lung fibrosis was prevented in mice by introduction of the inhibitory Smad7 gene via in vivo [14] , and the administration of anti-TGF␤ antibodies prevented cutaneous hyperplasia in a model for chronic graft versus host disease [15] . In addition, disruption of the TGF␤1 gene prevented skin fibrosis in tight skin mice [16] .
In summary, NIH 3T3 fibroblasts containing a transgene, TGF␤1, showed sustained TGF␤1 expression and induced cavernous fibrosis that lasted for more than 20 days, whereas a single dose of rhTGF␤1 did not result in cavernous fibrosis. We think that a cell-mediated approach to gene delivery using fibroblasts secreting TGF␤1 is a useful, costeffective method for establishing a long-lasting model of cavernous fibrosis. This model may contribute to further investigation of the pathogenesis of penile fibrosis associated with TGF␤1 signaling and to the development of new therapeutics targeting this pathway in vasculogenic ED.
